Skip to main content

NEWSBRIEF: Pharsight Inks Deal to Supply Aventis with Software and Support

SAN FRANCISCO, April 30 - Pharsight said today that it will supply software and support to Aventis Pharma for clinical development of four of the pharmaceutical company's drug candidates.

 

The multi-year deal caps a one year proof-of-product period where Pharsight applied modeling and simulation to an Aventis project, Pharsight said.

 

Aventis' software integrates its computer-based modeling of scientific, clinical, commercial, and financial information about a drug candidate to create models and simulations to help steer drug development.

 

Details of the agreement were not disclosed.

 

Pharsight said this was its largest customer deal to date.

 

For more information, click here.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.